VistaGen Story

Will VistaGen Therapeutics (NASDAQ:VTGN) price continue to rise in February?
Using predictive technical analysis, we will analyze different prices and returns patterns and diagnose historical swings to determine the real value of VistaGen Therapeutics. In general, we focus on analyzing VistaGen Therapeutics stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build VistaGen Therapeutics's daily price indicators and compare them against related drivers such as momentum indicators and various other types of predictive indicators. Using this methodology combined with a more conventional technical analysis and fundamental analysis, we attempt to find the most accurate representation of VistaGen Therapeutics's intrinsic value. In addition to deriving basic predictive indicators for VistaGen Therapeutics, we also check how macroeconomic factors affect VistaGen Therapeutics price patterns. Please read more on our technical analysis page or use our predictive modules below to complement your research. Sophisticated investors, who have witnessed many market ups and downs, frequently view the market will even out over time. This tendency of VistaGen Therapeutics' stock price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy. Please use the tools below to analyze the current value of VistaGen Therapeutics in the context of predictive analytics.

Hype Prediction Details

Intrinsic Valuation Details

Naive Forecast Details

1 Analysts Consensus Details

Please note, it is not enough to conduct a financial or market analysis of a single entity such as VistaGen Therapeutics. Your research has to be compared to or analyzed against VistaGen Therapeutics' peers to derive any actionable benefits. When done correctly, VistaGen Therapeutics' competitive analysis will give you plenty of quantitative and qualitative data to validate your investment decisions or develop an entirely new strategy towards taking a position in VistaGen Therapeutics.

How does VistaGen Stands against Peers?

Analyzing VistaGen Therapeutics competition or peers my help you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Try to analyze the advantages of investing in traded instruments related to VistaGen Therapeutics across multiple sectors and thematic ideas. A good competitive analysis can cover a lot of different areas. But what areas to choose depends on who you are. The more exhaustive you are in your analysis, the more effective your competitive analysis will be. Check out VistaGen Therapeutics Competition Details

How VistaGen utilizes its cash?

To perform a cash flow analysis of VistaGen Therapeutics, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash VistaGen Therapeutics is receiving and how much cash it distributes out in a given period. The VistaGen Therapeutics cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities.

VistaGen Therapeutics exotic insider transaction detected

Legal trades by VistaGen Therapeutics insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

VistaGen insider trading alert for general transaction of common stock by Jon Saxe, the corporate stakeholder, on 24th of August 2020. This event was filed by Vistagen Therapeutics Inc with SEC on 2020-08-24. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

About Contributor